An advisory panel to the Food and Drug Administration voted 8 to 4 on Thursday against recommending approval of a Lyme disease vaccine developed by Pfizer and Valneva, concluding that the available data were insufficient to support a positive benefit-risk determination at this stage of the development program.

The panel's majority did not dispute the vaccine's efficacy data, which showed 89 percent protection against confirmed Lyme disease across more than 6,000 participants in phase 3 trials. Its central objection was the 18-month follow-up period, which the majority concluded was too short to rule out delayed adverse events with adequate confidence. The panel chair acknowledged the strength of the efficacy findings but said the committee's responsibility extended beyond the immediate trial window. "The science is genuinely promising," she said. "But we need it to be complete before we act."

The caution was informed by the history of LYMErix, the only previously licensed Lyme vaccine in the United States, which was withdrawn from the market in 2002 after post-approval reports of arthritis-like symptoms. Subsequent studies found those reports to be unsubstantiated, but the episode generated a regulatory legacy that several panel members referenced directly in their comments. "We have seen what happens when we move too quickly in this specific space," one panel member said. "The 18-month follow-up does not give us enough to say definitively that we have not missed something."

The four dissenting panel members argued that the majority was applying a standard inconsistent with other approved vaccines and that the combination of 89 percent efficacy data and the scale of Lyme disease burden — approximately 476,000 Americans are diagnosed annually — made rejection the wrong outcome. "We manage residual uncertainty with post-market surveillance," one dissenting member said. "That is what it exists for. Rejecting a vaccine with these efficacy numbers because we want more follow-up is a choice with consequences for patients."

Patient advocates who had attended the hearing and submitted testimony in large volumes reacted with visible disappointment to the vote. One representative of a Lyme disease patient coalition told reporters outside the hearing room that the decision was "another generation of patients being left without a tool that could protect them."

Pfizer and Valneva issued a joint statement saying they were "deeply disappointed" by the vote and were evaluating all available options, including resubmission with extended follow-up data from an ongoing trial extension. The companies noted that regulatory processes in Europe and other jurisdictions remained active and that the clinical development program would continue.

The FDA is not required to follow its advisory committee votes. A final agency decision on the application remains pending and is expected within the standard review window.